Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.43 +0.52 (+4.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
NovoCure's Return On Capital Employed Insights
NovoCure (NASDAQ:NVCR) brought in sales totaling $131.00 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 10.7%, resulting in a loss of $26.58 million. 
Via Benzinga
3 Unstoppable Stocks That Could Double in 5 Years
The opportunities for these innovators are tremendous. 
Via The Motley Fool
What 4 Analyst Ratings Have To Say About NovoCure
Analysts have provided the following ratings for NovoCure (NASDAQ:NVCR) within the last quarter: 
Via Benzinga
Where NovoCure Stands With Analysts
NovoCure (NASDAQ:NVCR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Novocure (NVCR) Q3 2022 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2022. 
Via The Motley Fool
NovoCure: Q3 Earnings Insights
NovoCure (NASDAQ:NVCR) reported its Q3 earnings results on Thursday, October 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings NovoCure beat estimated earnings... 
Via Benzinga
Why Novocure Stock Is Sinking Today
An analyst's downgrade is weighing on the biotech company. 
Via The Motley Fool
The Clock Is Ticking to Buy This Game-Changing Stock at a Discount
This stock could soon skyrocket. 
Via The Motley Fool
Recap: NovoCure Q2 Earnings
  NovoCure (NASDAQ:NVCR) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Novocure Reports Third Quarter 2022 Financial Results
From Novocure
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
Upgrades 
Via Benzinga
CSX To Rally 20%? Here Are 5 Other Price Target Changes For Monday
Raymond James raised CSX Corporation (NASDAQ: CSX) price target from $31 to $33. Raymond James analyst Patrick Tyler Brown maintained the stock with an Outperform rating. CSX shares rose 1.7% to close... 
Via Benzinga
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
From Novocure
Via Business Wire
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
From Novocure
Via Business Wire
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
From Novocure
Via Business Wire
3 Unstoppable Stocks You Can Buy Now for Less Than $100
They might not be available so cheaply for too much longer. 
Via The Motley Fool
Novocure to Report Third Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
From Novocure
Via Business Wire
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
From Novocure
Via Business Wire
NovoCure Earnings Perspective: Return On Capital Employed
NovoCure (NASDAQ:NVCR) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 416.63%, resulting in a loss of $24.01 million. 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novocure Reports Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2022
Upgrades 
Via Benzinga
Novocure to Report Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
From Novocure
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.